Lonza Biologics Inc.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

Tanvex BioPharma appoints Stephen Lam as CEO, effective September 5, 2024. Lam will oversee integration with Bora Pharmaceuticals, driving strategic initiatives and managing global CDMO operations. With over 35 years of industry experience, Lam aims to expand Tanvex's global presence and accelerate growth.

US regulators will accept alternatives to horseshoe crab blood for drug quality assurance testing in November, easing industry reliance on the animal.

Kivu Biosciences raised $92M in Series A to advance its ADC technology, aiming for more precise and stable drugs to reduce side effects, with plans for a solid tumor clinical trial in 2024. Novo Holdings led the round, joined by six other venture firms.

The global Biotechnology and Pharmaceutical Services Outsourcing market size is expected to grow from USD 48.25 billion in 2024 to USD 83.28 billion by 2034, with a CAGR of 5.61%. Key segments include consulting services (24% share in 2024), regulatory affairs (highest CAGR of 8.37%), and pharmaceutical companies (60% share in 2024). North America dominates the market, driven by strong CMOs and CROs presence, while Asia Pacific is expected to grow fastest due to increasing investments and reforms.

Lonza extends collaboration with a global biopharmaceutical partner for ADC commercial-scale manufacture, including new bioconjugation suite construction in Visp (CH) and mAb manufacturing for a new ADC therapy. The suite, operational in 2027, will support highly-potent modalities and create 100 new jobs.

The North America Cell and Gene Therapy Manufacturing QC Market is projected to grow from USD 1,081.20 million in 2025 to USD 6,569.31 million by 2033, at a CAGR of 25.3%. Key drivers include increasing clinical trials and investments, rising therapy approvals, and advanced biopharmaceutical companies. High QC infrastructure costs are a restraint, while expansion of contract QC services offers opportunities.

The biotech and pharmaceutical industries impact lives and economies, employing over 1,500 facilities across the U.S. with high-paying jobs. Despite recent revenue drops post-pandemic, innovation and M&A activity are driving future sales. Frederick County, Maryland, is a thriving hub for life sciences, offering proximity to key research institutions, a skilled workforce, and business-friendly policies.

Advances in precision medicine have transformed NSCLC treatment, with broad molecular testing now recommended. HER2 mutation, present in 3% of NSCLC patients, is associated with aggressive disease and brain metastases. No first-line HER2-targeted therapies are approved; current options include immunotherapy and platinum doublet. Zongertinib and BAY 2927088, oral HER2-targeted TKIs, show promise in pre-treated patients, with zongertinib demonstrating a 66.7% ORR and BAY 2927088 showing a 72.1% ORR. Both agents have been granted breakthrough therapy designation by the FDA.

The mRNA synthesis & manufacturing market is projected to reach USD 738.3 million by 2029, driven by mRNA vaccine development and technology advancements. Consumables dominate the market, with pharmaceutical and biotechnology companies leading as end users. Asia Pacific is expected to grow fastest due to increased healthcare expenditure and investments in biopharmaceuticals.